Palm Therapeutics: Preclinical Development of NRAS Palmitoylation Inhibitors for NRAS Mutant Cancers

Novel Approaches and New Therapeutic Platforms

Andrew Rudd, PhD

Half a million patients in the United States suffer from cancers that are driven by mutant forms of the protein NRAS. Unfortunately, there are a lack of effective drugs that target NRAS, resulting in poor clinical outcomes for these patients. We are overcoming prior hurdles to developing NRAS-targeted therapies by developing drugs that inhibit NRAS palmitoylation, a fatty acid modification essential for its cancer- driving function. This project will fund critical pre-clinical research and development activities in our NRAS program and support our goal of reaching First-in-Human trials by 2028.

“At Palm Therapeutics, we are committed to developing new therapies for some of the most difficult to treat cancers. We are thrilled and honored to receive the Catalyst Grant, which will help us reach key scientific milestones in our NRAS inhibitor program and support our ultimate mission of providing better treatment options for NRAS-mutant cancer patients.” – Andrew Rudd, PhD